Pearl M - Search Results

1

Activation of EDTA-resistant gelatinases in malignant human tumors.

Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen WT. Chen D, et al. Among authors: pearl m. Cancer Res. 2006 Oct 15;66(20):9977-85. doi: 10.1158/0008-5472.CAN-06-1499. Cancer Res. 2006. PMID: 17047060 Free PMC article.

2

Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.

Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Fan T, et al. Gynecol Oncol. 2009 Jan;112(1):185-91. doi: 10.1016/j.ygyno.2008.09.021. Epub 2008 Oct 26. Gynecol Oncol. 2009. PMID: 18954898 Free PMC article.

3

Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.

Pearl ML, Zhao Q, Yang J, Dong H, Tulley S, Zhang Q, Golightly M, Zucker S, Chen WT. Pearl ML, et al. Gynecol Oncol. 2014 Sep;134(3):581-90. doi: 10.1016/j.ygyno.2014.06.013. Epub 2014 Jun 24. Gynecol Oncol. 2014. PMID: 24972191 Free PMC article.

4

Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

Pearl ML, Dong H, Tulley S, Zhao Q, Golightly M, Zucker S, Chen WT. Pearl ML, et al. Gynecol Oncol. 2015 May;137(2):229-38. doi: 10.1016/j.ygyno.2015.03.002. Epub 2015 Mar 11. Gynecol Oncol. 2015. PMID: 25769657 Free PMC article.

5

Vita-Assay™ Method of Enrichment and Identification of Circulating Cancer Cells/Circulating Tumor Cells (CTCs).

Tulley S, Zhao Q, Dong H, Pearl ML, Chen WT. Tulley S, et al. Methods Mol Biol. 2016;1406:107-19. doi: 10.1007/978-1-4939-3444-7_9. Methods Mol Biol. 2016. PMID: 26820949

6

Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, Powell MA, Backes FJ, Mathews CA, Pearl ML, Secord AA, Peace DJ, Mutch DG, Creasman WT, Kim JJ. Winder AD, et al. Among authors: pearl ml. Cancer. 2017 Apr 1;123(7):1144-1155. doi: 10.1002/cncr.30477. Epub 2016 Dec 7. Cancer. 2017. PMID: 27926776 Free PMC article.

7

iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.

Pearl ML, Dong H, Zhao Q, Tulley S, Dombroff MK, Chen WT. Pearl ML, et al. Gynecol Oncol. 2017 Nov;147(2):426-432. doi: 10.1016/j.ygyno.2017.08.018. Epub 2017 Aug 19. Gynecol Oncol. 2017. PMID: 28830645 Free article.

8

The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness.

Dong H, Tulley S, Zhao Q, Cho L, Chen D, Pearl ML, Chen WT. Dong H, et al. Cancer Med. 2019 Jul;8(8):3864-3874. doi: 10.1002/cam4.2218. Epub 2019 May 21. Cancer Med. 2019. PMID: 31115187 Free PMC article.

9

Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients.

Pearl ML, Fischer M, McCauley DL, Valea FA, Chalas E. Pearl ML, et al. Cancer Nurs. 1999 Aug;22(4):307-11. doi: 10.1097/00002820-199908000-00008. Cancer Nurs. 1999. PMID: 10452208 Clinical Trial.

10

Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.

Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang B, Fadare O, Schwartz PE, Chambers SK, Kong B, Zheng W. Liang SX, et al. Among authors: pearl m. Int J Cancer. 2011 Feb 15;128(4):763-70. doi: 10.1002/ijc.25395. Int J Cancer. 2011. PMID: 20473885 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

374 results

Search Page